Literature DB >> 27236103

Myeloid-Derived Suppressor Cells in Psoriasis Are an Expanded Population Exhibiting Diverse T-Cell-Suppressor Mechanisms.

Lauren Y Cao1, Jin-Sung Chung1, Takahiro Teshima1, Lawrence Feigenbaum1, Ponciano D Cruz1, Heidi T Jacobe1, Benjamin F Chong1, Kiyoshi Ariizumi2.   

Abstract

Psoriasis vulgaris is an inflammatory skin disease caused by hyperactivated T cells regulated by positive and negative mechanisms; although the former have been much studied, the latter have not. We studied the regulatory mechanism mediated by myeloid-derived suppressor cells (MDSCs) and showed that MDSCs expanded in melanoma patients express dendritic cell-associated heparan sulfate proteoglycan-dependent integrin ligand, a critical mediator of T-cell suppressor function. We examined expansion of DC-HIL(+) MDSCs in psoriasis and characterized their functional properties. Frequency of DC-HIL(+) monocytic MDSCs (CD14(+)HLA-DR(no/low)) in blood and skin was markedly increased in psoriatic patients versus healthy control subjects, but there was no statistically significant relationship with disease severity (based on Psoriasis Area and Severity Index score). Blood DC-HIL(+) MDSC levels in untreated patients were significantly higher than in treated patients. Compared with melanoma-derived MDSCs, psoriatic MDSCs exhibited significantly reduced suppressor function and were less dependent on DC-HIL, but they were capable of inhibiting proliferation and IFN-γ and IL-17 responses of autologous T cells. Psoriatic MDSCs were functionally diverse among patients in their ability to suppress allogeneic T cells and in the use of either IL-17/arginase I or IFN-γ/inducible nitric oxide synthase axis as suppressor mechanisms. Thus, DC-HIL(+) MDSCs are expanded in psoriasis patients, and their mechanistic heterogeneity and relative functional deficiency may contribute to the development of psoriasis.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27236103      PMCID: PMC4992618          DOI: 10.1016/j.jid.2016.02.816

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  49 in total

1.  DC-HIL is a negative regulator of T lymphocyte activation.

Authors:  Jin-Sung Chung; Kota Sato; Irene I Dougherty; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

Review 2.  MDSC in autoimmunity.

Authors:  James G Cripps; James D Gorham
Journal:  Int Immunopharmacol       Date:  2011-02-21       Impact factor: 4.932

Review 3.  Psoriasis as autoinflammatory disease.

Authors:  Joaquin J Rivas Bejarano; Wendell C Valdecantos
Journal:  Dermatol Clin       Date:  2013-06-14       Impact factor: 3.478

Review 4.  OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology.

Authors:  Naoto Ishii; Takeshi Takahashi; Pejman Soroosh; Kazuo Sugamura
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

Review 5.  The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity.

Authors:  Je-In Youn; Dmitry I Gabrilovich
Journal:  Eur J Immunol       Date:  2010-11       Impact factor: 5.532

6.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Authors:  Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

7.  A possible pathogenic role of CD4+CD25+ T-regulatory cells in psoriasis.

Authors:  Iman H Shehata; Tarek M Elghandour
Journal:  Egypt J Immunol       Date:  2007

8.  The DC-HIL ligand syndecan-4 is a negative regulator of T-cell allo-reactivity responsible for graft-versus-host disease.

Authors:  Jin-Sung Chung; Mizuki Tomihari; Kyoichi Tamura; Tetsuhito Kojima; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

9.  IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis.

Authors:  Jason R Chan; Wendy Blumenschein; Erin Murphy; Caroline Diveu; Maria Wiekowski; Susan Abbondanzo; Linda Lucian; Richard Geissler; Scott Brodie; Alexa B Kimball; Daniel M Gorman; Kathleen Smith; Rene de Waal Malefyt; Robert A Kastelein; Terrill K McClanahan; Edward P Bowman
Journal:  J Exp Med       Date:  2006-10-30       Impact factor: 14.307

10.  DC-HIL+ CD14+ HLA-DR no/low cells are a potential blood marker and therapeutic target for melanoma.

Authors:  Jake Turrentine; Jin-Sung Chung; Kaveh Nezafati; Kyoichi Tamura; Amy Harker-Murray; James Huth; Rohit R Sharma; David B Harker; Kiyoshi Ariizumi; Ponciano D Cruz
Journal:  J Invest Dermatol       Date:  2014-06-16       Impact factor: 8.551

View more
  13 in total

Review 1.  GPNMB: a potent inducer of immunosuppression in cancer.

Authors:  Anna-Maria Lazaratos; Matthew G Annis; Peter M Siegel
Journal:  Oncogene       Date:  2022-09-01       Impact factor: 8.756

2.  Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients.

Authors:  Masato Kobayashi; Jin-Sung Chung; Muhammad Beg; Yull Arriaga; Udit Verma; Kevin Courtney; John Mansour; Barbara Haley; Saad Khan; Yutaka Horiuchi; Vijay Ramani; David Harker; Purva Gopal; Farshid Araghizadeh; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Clin Cancer Res       Date:  2018-07-26       Impact factor: 12.531

3.  A novel MDSC-induced PD-1-PD-L1+ B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties.

Authors:  Meng Shen; Jian Wang; Wenwen Yu; Chen Zhang; Min Liu; Kaiyuan Wang; Lili Yang; Feng Wei; Shizhen Emily Wang; Qian Sun; Xiubao Ren
Journal:  Oncoimmunology       Date:  2018-02-20       Impact factor: 8.110

4.  Healthy myeloid-derived suppressor cells express the surface ectoenzyme Vanin-2 (VNN2).

Authors:  David C Soler; Amber Kerstetter-Fogle; Andrew B Young; Pat Rayman; James H Finke; Sarah M Debanne; Kevin D Cooper; Jill Barnholtz-Sloan; Andrew E Sloan; Thomas S McCormick
Journal:  Mol Immunol       Date:  2021-12-23       Impact factor: 4.407

Review 5.  ER stress activates immunosuppressive network: implications for aging and Alzheimer's disease.

Authors:  Antero Salminen; Kai Kaarniranta; Anu Kauppinen
Journal:  J Mol Med (Berl)       Date:  2020-04-11       Impact factor: 4.599

6.  Targeting Myeloid-Derived Suppressor Cells Is a Novel Strategy for Anti-Psoriasis Therapy.

Authors:  Chao Chen; Lirong Tan; Wu Zhu; Li Lei; Yehong Kuang; Panpan Liu; Jie Li; Xiang Chen; Cong Peng
Journal:  Mediators Inflamm       Date:  2020-06-28       Impact factor: 4.711

7.  Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus.

Authors:  Saifur Rahman; Divya Sagar; Richard N Hanna; Yaima L Lightfoot; Pragnesh Mistry; Carolyne K Smith; Zerai Manna; Sarfaraz Hasni; Richard M Siegel; Miguel A Sanjuan; Roland Kolbeck; Mariana J Kaplan; Kerry A Casey
Journal:  Ann Rheum Dis       Date:  2019-04-30       Impact factor: 19.103

Review 8.  Targeting T Cell Metabolism in Inflammatory Skin Disease.

Authors:  Leonhard von Meyenn; Nicole Leonie Bertschi; Christoph Schlapbach
Journal:  Front Immunol       Date:  2019-09-24       Impact factor: 7.561

Review 9.  Myeloid-Derived Suppressor Cells: Ductile Targets in Disease.

Authors:  Francesca Maria Consonni; Chiara Porta; Arianna Marino; Chiara Pandolfo; Silvia Mola; Augusto Bleve; Antonio Sica
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

10.  Circulating CD14+HLA-DR-/low Myeloid-Derived Suppressor Cells as Potential Biomarkers for the Identification of Psoriasis TCM Blood-Heat Syndrome and Blood-Stasis Syndrome.

Authors:  Shipeng Sun; Yali Wei; Xue Zeng; Yuliang Yuan; Na Wang; Cheng An; Jinlong Duan; Bo Pang; Zifu Hong; Guijian Liu
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-14       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.